p53 activation: a checkpoint for precision genome editing?

Recent work has reported that the activation of the p53 pathway in primary cells hampers the efficiency of genome editing by CRISPR/Cas9 via induction of apoptosis or cell cycle arrest. These findings highlight the importance of wholly comprehending cellular responses to programmable nucleases in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Conti, Anastasia, Di Micco, Raffaella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098583/
https://www.ncbi.nlm.nih.gov/pubmed/30119695
http://dx.doi.org/10.1186/s13073-018-0578-6
_version_ 1783348505773867008
author Conti, Anastasia
Di Micco, Raffaella
author_facet Conti, Anastasia
Di Micco, Raffaella
author_sort Conti, Anastasia
collection PubMed
description Recent work has reported that the activation of the p53 pathway in primary cells hampers the efficiency of genome editing by CRISPR/Cas9 via induction of apoptosis or cell cycle arrest. These findings highlight the importance of wholly comprehending cellular responses to programmable nucleases in therapeutically relevant cell types to fulfill the promise of genome editing for therapeutic applications for human diseases.
format Online
Article
Text
id pubmed-6098583
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60985832018-08-23 p53 activation: a checkpoint for precision genome editing? Conti, Anastasia Di Micco, Raffaella Genome Med Comment Recent work has reported that the activation of the p53 pathway in primary cells hampers the efficiency of genome editing by CRISPR/Cas9 via induction of apoptosis or cell cycle arrest. These findings highlight the importance of wholly comprehending cellular responses to programmable nucleases in therapeutically relevant cell types to fulfill the promise of genome editing for therapeutic applications for human diseases. BioMed Central 2018-08-17 /pmc/articles/PMC6098583/ /pubmed/30119695 http://dx.doi.org/10.1186/s13073-018-0578-6 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Comment
Conti, Anastasia
Di Micco, Raffaella
p53 activation: a checkpoint for precision genome editing?
title p53 activation: a checkpoint for precision genome editing?
title_full p53 activation: a checkpoint for precision genome editing?
title_fullStr p53 activation: a checkpoint for precision genome editing?
title_full_unstemmed p53 activation: a checkpoint for precision genome editing?
title_short p53 activation: a checkpoint for precision genome editing?
title_sort p53 activation: a checkpoint for precision genome editing?
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098583/
https://www.ncbi.nlm.nih.gov/pubmed/30119695
http://dx.doi.org/10.1186/s13073-018-0578-6
work_keys_str_mv AT contianastasia p53activationacheckpointforprecisiongenomeediting
AT dimiccoraffaella p53activationacheckpointforprecisiongenomeediting

Ejemplares similares